| Ytd | 42.44% | |
| 1y | 16.27% |
| Open | 4.07 | Prev Close | 4.09 | Low | 3.84 | High | 4.10 | Mkt Cap | 165.21M |
| Vol | 643.90K | Avg Vol | 1.28M | EPS | -1.04 | P/E | N/A | Forward P/E | -1.12 |
| Beta | 1.27 | Short Ratio | 4.80 | Inst. Own | 6.05% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-14 | 50-d Avg | 3.55 | 200-d Avg | 2.70 | 1yr Est | 31.67 |
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx" or the "Company") today issued the fo
WILMINGTON, Del., June 25, 2026 (GLOBE NEWSWIRE) -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx”
First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and S
First Zeta-navigated TMS treatments have begun at HOPE Therapeutics clinics in West Palm Beach and S
D-Cycloserine (DCS) has been reported to augment the effect of Transcranial Magnetic Stimulation (TM
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a
Tetra Technologies Inc. (NYSE: TTI) shares fell 15.06% in pre-market trading after announcing a $100
NRXP stock fell after hours after NRx Pharmaceuticals announced a public stock offering to raise cap
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx Pharmaceuticals" or the "Company"), a